CLINICAL-TRIAL OF INDOMETHACIN IN ALZHEIMERS-DISEASE

In a 6-month, double-blind, placebo-controlled study, 100 to 150 mg/d indomethacin appeared to protect mild to moderately impaired Alzheimer 's disease patients from the degree of cognitive decline exhibited by a well-matched, placebo-treated group. Over a battery of cognitive tes ts, indomethacin patients improved 1.3% (+/-1.8%), whereas placebo pat ients declined 8.4% (+/-2.3%)-a significant difference (p < 0.003). Ca veats include adverse reactions to indomethacin and the limited scale of the trial.